Patents Assigned to Zoetis Belgium S.A
  • Patent number: 10456463
    Abstract: Described are vaccines having one or more antigens cholesterol and CpG. Aspects of the invention relate to the use of the vaccines of the invention for the treatment and/or prevention of human and animal disorders.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: October 29, 2019
    Assignee: Zoetis Belgium S.A
    Inventors: Heather Lynn Davis, Risini Weeratna, Paul J. Dominowski
  • Patent number: 10125192
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: November 13, 2018
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Patent number: 10093725
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 9, 2018
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Patent number: 9505829
    Abstract: The present disclosure encompasses NGF binding proteins, specifically to antibodies that are chimeric, CDR grafted and canonized antibodies, and methods of making and uses thereof. The antibodies, or antibody portions, of the disclosure are useful for detecting NGF and for inhibiting NGF activity, e.g., in a mammal subject suffering from a disorder in which NGF activity is detrimental.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: November 29, 2016
    Assignee: ZOETIS BELGIUM S.A.
    Inventors: Susan E. Lacy, Jeffrey A. Barbon, Meha Chhaya, Emma Fung, Charles W. Hutchins, Diane M. Lang, Eve H. Barlow, Mary Leddy, Ravi Chari
  • Patent number: 9168251
    Abstract: The present disclosure relates to a method of providing prolonged analgesia to a mammal in need thereof. Specifically, the current disclosure is directed to a method of treating pain in a mammal for a prolonged period of time using a single high dose of a buprenorphine formulation.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: October 27, 2015
    Assignee: Zoetis Belgium S.A
    Inventors: Rachel A. Richardson, Carmela H. Luangdilok, Luk Chiu Li